Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,306.80
(
0.96%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
99.89
(
-1.30%
)
Bitcoin
78,187.54
(
-0.12%
)
News Focus
News Focus
Post# of 257442
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: biotech_researcher post# 164145

Tuesday, 07/16/2013 6:26:21 PM

Tuesday, July 16, 2013 6:26:21 PM

Post# of 257442
According to the Credit Suisse report, "Gleevec/Glivec is used much more frequently in the first line setting in the EU than the US (74% vs. 46%)." Using those percentages, until the EPIC results are in, Iclusig only has the possibility of being used in second-line 26% of the time in the EU (other than T315I).
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today